Net proceeds are intended to fund a potential commercial launch of INO-3107, a recurrent respiratory papillomatosis candidate under FDA review with a target decision date of October 30, as well as a confirmatory trial for INO-3107 if required, pipeline development, and general corporate purposes
doi: 10.3389/fendo.2026.1762596 Received 07 December 2025 Revised 21 February 2026 Accepted 02 March 2026 Published 16 March 2026 Volume 17 - 2026 Edited by Claire Joanne Stocker, Aston University, United Kingdom Reviewed by Damasia Becu-Villalobos, CONICET Institute of Biology and Experimental Medicine (IBYME), Argentina Edward Wargent, University of Buckingham, United Kingdom Dzilda Velickiene, Hospital of Lithuanian University of Health Sciences Kaunas Clinics, Lithuania Updates Copyright 2026 Wang, Luo, Fang, Ge, Huang and Deng
Joe and his team offer free case reviews so you dont have to worry about additional costs just to speak with a qualified lawyer about what happened
Our sugar-free drinks have no nasty high levels of sugar and artificial ingredients and fillers in other commonly available energy drinks
